VIEWTRIX TECH (03310): Sign a guidance agreement for A-share listing
Yunying Valley Technology (03310) announced that after successfully listing on the stock exchange, the company has prudently assessed capital market opportunities. In order to promote business development, deepen industrial layout, and enhance the company's overall competitiveness, the company plans to initiate the process of issuing ordinary shares in Renminbi (A-shares) within China (proposed A-share listing).
VIEWTRIX TECH (03310) announced that after successfully listing on the Stock Exchange, the company is prudently assessing capital market opportunities to promote business development, deepen industry layout, and enhance comprehensive competitiveness. The company intends to initiate the process of issuing ordinary shares (A-shares) in Renminbi within China (proposed A-share listing). On September 2, 2026, the Board of Directors reviewed and approved the signing of a counseling agreement on stock issuance and listing between VIEWTRIX TECH and GF SEC Co., Ltd. (GF SEC), appointing GF SEC as the counseling institution for the proposed A-share listing, and will submit a filing application for the counseling of the proposed A-share listing to the relevant regulatory authorities in accordance with applicable laws and regulations. As of the date of this announcement, the Board has not approved any other plans related to the proposed A-share listing, nor has it applied for approval from any relevant regulatory authorities in China for the proposed A-share listing.
Related Articles

SIMCERE PHARMA (02096) invested HKD 10.7033 million to repurchase 929,000 shares, demonstrating the company's confidence in its long-term development.

CLOUDBREAK-B (02592) will be suspended from trading starting the morning of September 10.

INSILICO (03696): The company's leading AI-driven candidate innovative drug Rentosertib has completed the enrollment of its first patient in a Phase III clinical trial for idiopathic pulmonary fibrosis.
SIMCERE PHARMA (02096) invested HKD 10.7033 million to repurchase 929,000 shares, demonstrating the company's confidence in its long-term development.

CLOUDBREAK-B (02592) will be suspended from trading starting the morning of September 10.

INSILICO (03696): The company's leading AI-driven candidate innovative drug Rentosertib has completed the enrollment of its first patient in a Phase III clinical trial for idiopathic pulmonary fibrosis.

RECOMMEND





